AmacaThera, a developer of next-generation hydrogel-based drug delivery solutions, announced on Wednesday that it has been named Emerging Company of the Year by Life Sciences Ontario.
According to AmacaThera, this award highlights the company's evolution from an early-stage biotech into a global innovator, reflecting recognition from the broader life sciences community for its scientific excellence, innovative hydrogel technology, and increasing influence within the sector.
Mike Cooke, AmacaThera's CEO, said: "We are honoured to receive this recognition from Life Sciences Ontario. It reflects the strength of our scientific innovation and the growing relevance of next-generation, hydrogel-based drug delivery solutions. As we evolve from an early-stage biotech into a global innovator, I am proud of our multidisciplinary team whose expertise and dedication have been instrumental in our progress."
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project